2026 – State Expert Center of the Ministry of Health of Ukraine

Patient card on the safe use of the medicinal product ENBREL® (etanercept)

11.09.2026 78

Patient card with safety information on the use of the medicinal product Enbrel® (etanercept): warnings about the risk of infections, the need for tuberculosis screening, recording of treatment data and reporting of adverse reactions. Intended for patients using this medicine and their doctors. compiled automatically

Patient information cards on the safe use of the medicinal product Hyrimoz (adalimumab)

08.09.2026 92

Safety information cards for adult and pediatric patients receiving the medicinal product Hyrimoz (adalimumab), and for physicians who prescribe it. They contain key information on possible adverse reactions, warnings regarding infections, tuberculosis, cancer, and vaccination, and recommendations for monitoring during treatment. generated automatically

Communication materials for patients on the safety of use of the medicinal product MITOXANTRONE “EBEWE

17.08.2026 93

Information material for patients receiving treatment with mitoxantrone for highly active relapsing multiple sclerosis. Contains a description of serious cardiovascular, hematological and genotoxic risks and recommendations for reducing them. generated automatically

Patient guide on the safe use of the medicinal product XENPOMA (pomalidomide)

14.08.2026 145

Patient guide on the safe use of the medicinal product Xenpoma (pomalidomide), containing information on the Pregnancy Prevention Program, risks to the fetus, rules for handling the medicine, disposal of capsules and restrictions on blood donation. compiled automatically

Communication materials on the safe use of the medicinal product HEMLIBRA® (emicizumab). Guide for the patient/caregiver and Patient reminder card

14.08.2026 109

This is educational material for patients and caregivers intended for the safe use of a medicinal product in the treatment of hemophilia A. It contains recommendations for minimizing important risks, in particular regarding the effect on laboratory blood coagulation tests and serious adverse reactions. generated automatically

Patient guide for the medicinal product CELLCEPT® (mycophenolate mofetil), information on risks to the unborn child

14.08.2026 100

Educational guide for patients who take mycophenolate mofetil and may become pregnant. Contains information on the risks of spontaneous abortion and congenital malformations and ways to reduce them. generated automatically

Patient information card: important information about combined hormonal contraceptives and the risk of blood clots. Risk minimization when using the medicinal product DESOFEMINE® 30

07.08.2026 149

Information card for female patients using combined hormonal contraceptives containing ethinylestradiol/desogestrel. It contains a list of factors that increase the risk of thrombosis, symptoms that require urgent medical attention, and recommendations on informing healthcare professionals. generated automatically

Patient reminder card on the safety of use of the medicinal product Edoxacord (edoxaban)

28.07.2026 177

A reminder card for patients taking the anticoagulant medicinal product Edoxacord (edoxaban): it contains fields to be completed by the doctor, intake recommendations, signs of bleeding, and information for healthcare and pharmacy professionals. compiled automatically

Patient information card on the safe use of the medicinal product ZOLTERO (zoledronic acid): minimizing the risk of osteonecrosis of the jaw

20.07.2026 125

Reminder card for patients receiving zoledronic acid treatment on the risk of osteonecrosis of the jaw. Contains recommendations on precautions before and during therapy, including dental care. generated automatically

Patient guide on the safe use of the medicinal product MIKOP (mycophenolate mofetil).

20.07.2026 114

Educational guide for patients who use mycophenolate mofetil and may become pregnant. Contains information on the risks of miscarriage and congenital malformations for the unborn child, contraception, pregnancy planning, and ways to reduce these risks. compiled automatically

Patient card on the safe use of the medicinal product ENBREL® (etanercept)

Patient information cards on the safe use of the medicinal product Hyrimoz (adalimumab)

Communication materials for patients on the safety of use of the medicinal product MITOXANTRONE “EBEWE

Patient guide on the safe use of the medicinal product XENPOMA (pomalidomide)

Communication materials on the safe use of the medicinal product HEMLIBRA® (emicizumab). Guide for the patient/caregiver and Patient reminder card

Patient guide for the medicinal product CELLCEPT® (mycophenolate mofetil), information on risks to the unborn child

Patient information card: important information about combined hormonal contraceptives and the risk of blood clots. Risk minimization when using the medicinal product DESOFEMINE® 30

Patient reminder card on the safety of use of the medicinal product Edoxacord (edoxaban)

Patient information card on the safe use of the medicinal product ZOLTERO (zoledronic acid): minimizing the risk of osteonecrosis of the jaw

Patient guide on the safe use of the medicinal product MIKOP (mycophenolate mofetil).

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration